Skip to main content
. 2021 Nov 18;225(4):603–607. doi: 10.1093/infdis/jiab575

Figure 1.

Figure 1.

Vaccination rates among Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants and the general population. A, Kaplan-Meier curve depicting probability of vaccination among REPRIEVE participants through July 2021. B, Kaplan-Meier curve depicting probability of vaccination among REPRIEVE participants by Global Burden of Disease (GBD) superregion. C, Comparisons of vaccination rates between people with HIV in REPRIEVE and the general and eligible populations among GBD superregions.